AbbVie Inc. (ABBV)
AbbVie Down 3% in a Month: Why Holding the Stock Still Makes Sense
ABBV stock falls 3% in a month amid takeover rumor denials, but Skyrizi and Rinvoq momentum and a deep pipeline support staying invested.
AbbVie, RemeGen partner on experimental solid tumor treatment
AbbVie said on Monday it would partner with RemeGen to develop an experimental treatment for solid tumors in a deal worth up to $4.95 billion, including milestones.
3 No-Brainer Dividend Stocks to Buy Right Now
AbbVie is a Dividend King in growth mode. Enbridge offers an attractive dividend plus both safety and growth potential.
MoneyShow's Best Investment Ideas For 2026: Part 1
MoneyShow presents top investment ideas for 2026 from their contributors. This year's edition presents a mix of metals plays, financial stocks, deep value names, high-octane growth and tech stocks, and beaten-down REITs that offer solid income and turnaround potential. Part 1 of this series includes AbbVie, Alexandria Real Estate Equities, Arbor Realty Trust, Archer Aviation, and Ares Management Corp., among others.
Here's What We Expect From AbbVie's Immunology Segment in Q4
ABBV's Q4 outlook hinges on surging Skyrizi and Rinvoq demand, as investors watch immunology sales to offset Humira's past loss of exclusivity.
AbbVie: The Dividend Does Not Lie
AbbVie Inc. maintains its Hold rating, as its latest dividend raise signals near-term earnings pressure and a decelerating growth trend. ABBV's Q1 2026 dividend increases 5.5% YOY, lagging both its past growth rates and the healthcare sector median. Current valuation appears stretched, with ABBV stock trading at 23.5x P/E and a PEGY ratio of 1.41x.
AbbVie Near Deal for Revolution Medicines
The cancer-drug biotech firm has a market value around $16 billion.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
What Can Trigger A Breakout In Abbvie Stock?
AbbVie stock (NYSE:ABBV) has exhibited considerable rally potential, having once achieved over a 50% increase in less than two months in 2020. Furthermore, the stock has undergone seven rallies surpassing 30% within comparable periods, including significant years such as 2017 and 2024.
AbbVie (ABBV) Stock Falls Amid Market Uptick: What Investors Need to Know
The latest trading day saw AbbVie (ABBV) settling at $220.18, representing a -3.98% change from its previous close.
AbbVie: Rocky Near-Term, Positive Long-Term
AbbVie outperformed the healthcare sector in 2025, but it remains to be seen whether the stock can repeat its performance in 2026. Last year, the stock was supported by relief for the pharmaceutical sector as MFN agreements were signed, its revenue growth was strong and earnings surpassed expectations. However, elevated forward P/E, potential MFN-driven profit pressure, and a market shift favoring cyclicals over defensives, can impact it negatively in 2026.
My Most Important Warning To Dividend Investors For 2026
The U.S. government is increasingly funding deficits with short-term debt, making interest expenses highly sensitive to Fed policy. A declining average maturity in the sovereign bond index tightens the link between fiscal and monetary policy, amplifying market complexity. Artificially subdued long-term bond supply likely keeps long-term yields lower than they would be with more balanced issuance.
